This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Anaxis Pharma Pty Ltd. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Christopher Gardner and Sulphonamide Compounds.
Introduction
Christopher Gardner is an inventor associated with Parkville, Australia, and Anaxis Pharma Pty Ltd. His patent work concerns sulphonamide compounds and their potential role in addressing necroptosis and MLKL activity.
Latest Patents
Gardner is associated with 1 patent, titled “Sulphonamide compounds.” The invention describes compounds of a specified formula, along with related salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs, and prodrugs. It also discloses their use to treat necroptosis and/or inhibit MLKL.
Career Highlights
The available information links Gardner’s patent activity to Anaxis Pharma Pty Ltd. The disclosed invention reflects research into compounds with potential applications in biological pathways involving necroptosis and MLKL.
Collaborations
Gardner’s listed coworkers include Jean-Marc Daniel Garnier and Martin Brzozowski. Their names are associated with the same research and patent context.
Conclusion
Christopher Gardner’s recorded invention focuses on sulphonamide compounds and their potential use in targeting necroptosis and MLKL, connecting his patent work with Anaxis Pharma Pty Ltd.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile